Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533646 | 0.89 | POLB (0.97) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL11561727 | 0.88 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL11037821 | 0.87 | POLB (0.87) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL18672819 | 0.86 | POLB (0.84) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL1246220 | 0.86 | TSHR (0.96) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL9067293 | 0.83 | POLB (0.85) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL30943574 | 0.83 | POLB (0.85) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL14180427 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL1148099 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAPOLBTSHRRECQL | |
| SCHEMBL296556 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAPOLBTSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637141-B1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | TROBIO AB (SE) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131234-A1 | SENSOR APPARATUS ADAPTED TO BE INCORPORATED IN A GARMENT | WEARABLE INFORMATION TECHNOLOGIES, S.L. (WEARTECH) (ES) | 2011-10-27 | — | — | WO | claimed |
| WO-2011014520-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-02-03 | — | — | WO | claimed |
| US-20090136474-A1 | Stabilized Protease Composition | TROBIO AB (SE) | 2009-05-28 | — | — | US | claimed |
| WO-2007035143-A1 | STABILIZED PROTEASE COMPOSITION | TROBIO AB (SE) | 2007-03-29 | — | — | WO | claimed |
| EP-1637141-A1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | Trobio AB (SE) | 2006-03-22 | — | — | EP | claimed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12269793-B2 | Affinity illudofulvene conjugates | AF CHEMICALS, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240358710-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | AF CHEMICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | AF CHEMICALS, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20090136474-A1 | Stabilized Protease Composition | TROBIO AB (SE) | 2009-05-28 | — | — | US | disclosed |
| EP-1673087-A4 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007035143-A1 | STABILIZED PROTEASE COMPOSITION | TROBIO AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| EP-1673087-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005032484-A9 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1637141-A1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | Trobio AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005032484-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | SMN1; SMN2 2596/4885LMNA 3179/4885POLB 1348/4885 |
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | SMN1; SMN2 3267/4885LMNA 3666/4885POLB 4746/4885 |
| US-20090136474-A1 | Stabilized Protease Composition | SERPINE1, SERPINB1, CTRL | SMN1; SMN2 655/4885LMNA 505/4885POLB 3135/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | SMN1; SMN2 3267/4885LMNA 3666/4885POLB 4746/4885 |
| US-20240358710-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | MYC, MYCBP, TP53 | SMN1; SMN2 2152/4885LMNA 3877/4885POLB 72/4885 |
| US-12269793-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | SMN1; SMN2 2596/4885LMNA 3179/4885POLB 1348/4885 |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | MYC, MYCBP, TP53 | SMN1; SMN2 2152/4885LMNA 3877/4885POLB 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.